BCDA Stock — Biocardia Inc

Biocardia Inc (BCDA)

Updated October 16, 2026.

BCDA is a Stock. Total return is -100.0% over the past 29.9 years, 1737.9 points behind SPY at 1637.9%.

BioCardia is a clinical-stage regenerative medicine company developing cellular therapies for cardiovascular and pulmonary diseases, with its lead candidate CardiAMP in Phase III trials for ischemic heart failure and refractory angina. The company does not currently distribute to shareholders. BioCardia appeals primarily to investors with high risk tolerance interested in early-stage biotech development rather than current income generation.

BCDA performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 29.9 years, 1737.9 points behind SPY at 1637.9%. Over the past year its total return — price change plus distributions reinvested — is -36.5%. Its deepest 1-year drawdown was 48.3%.

BCDA key facts

Asset type

Stock

Asset class

Equity

Inception date

11/13/1996

Distribution frequency

None

Last close

$0.92 (as of 2026-10-16)

Market cap

$13,929,193

Average volume

104788.0

Payment date

06/06/2019

Beta

0.616

Payout ratio

0.0%

EPS

$-0.64

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BCDA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 48.3%.

Who may consider BCDA — and who may not

It is a weaker fit for investors who need monthly cash flow (BCDA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BCDA

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions